{"id":"https://openalex.org/W587945571","doi":"https://doi.org/10.1159/000434723","title":"Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination 177Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy","display_name":"Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination 177Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy","alternate_titles":[],"publication_year":2015,"publication_date":"2015-06-10","ids":{"openalex":"https://openalex.org/W587945571","doi":"https://doi.org/10.1159/000434723","mag":"587945571","pmid":"https://pubmed.ncbi.nlm.nih.gov/26065489"},"language":"en","primary_location":{"id":"doi:10.1159/000434723","doi":"https://doi.org/10.1159/000434723","is_oa":false,"landing_page_url":"https://doi.org/10.1159/000434723","pdf_url":null,"source":{"id":"https://openalex.org/S84102376","display_name":"Neuroendocrinology","issn_l":"0028-3835","issn":["0028-3835","1423-0194"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310317820","host_organization_name":"Karger Publishers","host_organization_lineage":["https://openalex.org/P4310317820"],"host_organization_lineage_names":["Karger Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neuroendocrinology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W587945571"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5108471798","display_name":"Phillip G. Claringbold","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I177877127","display_name":"The University of Western Australia","ror":"https://ror.org/047272k79","country_code":"AU","type":"education","lineage":["https://openalex.org/I177877127"]}],"countries":["AU"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Phillip G. Claringbold","raw_affiliation_strings":["Oncology and","The University of Western, Australia#TAB#"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology and","institution_ids":[]},{"raw_affiliation_string":"The University of Western, Australia#TAB#","institution_ids":["https://openalex.org/I177877127"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5050960969","display_name":"J. Harvey Turner","orcid":"https://orcid.org/0000-0002-5254-9914","observed_orcids":["https://orcid.org/0000-0002-5254-9914"]},"institutions":[{"id":"https://openalex.org/I177877127","display_name":"The University of Western Australia","ror":"https://ror.org/047272k79","country_code":"AU","type":"education","lineage":["https://openalex.org/I177877127"]},{"id":"https://openalex.org/I2802692842","display_name":"Fremantle Hospital","ror":"https://ror.org/03yxgmm62","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I2799506148","https://openalex.org/I2800882159","https://openalex.org/I2802692842","https://openalex.org/I4388446375","https://openalex.org/I4388482742"]}],"countries":["AU"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"J. Harvey Turner","raw_affiliation_strings":["Nuclear Medicine, Fremantle Hospital, The University of Western Australia, Fremantle, W.A., Australia","The University of Western, Australia#TAB#"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nuclear Medicine, Fremantle Hospital, The University of Western Australia, Fremantle, W.A., Australia","institution_ids":["https://openalex.org/I177877127","https://openalex.org/I2802692842"]},{"raw_affiliation_string":"The University of Western, Australia#TAB#","institution_ids":["https://openalex.org/I177877127"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":3.8905,"has_fulltext":false,"cited_by_count":118,"citation_normalized_percentile":{"value":0.95584055,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":93,"max":99},"biblio":{"volume":"103","issue":"5","first_page":"432","last_page":"439"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10754","display_name":"Neuroendocrine Tumor Research Advances","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10754","display_name":"Neuroendocrine Tumor Research Advances","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10231","display_name":"Pancreatic and Hepatic Oncology Research","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12505","display_name":"Peptidase Inhibition and Analysis","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1303","display_name":"Biochemistry"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pancreatic-neuroendocrine-tumors","display_name":"pancreatic neuroendocrine tumors","score":0.9369999766349792},{"id":"https://openalex.org/keywords/177lu-octreotate","display_name":"177Lu-octreotate","score":0.9850000143051147},{"id":"https://openalex.org/keywords/capecitabine","display_name":"capecitabine","score":0.8759999871253967},{"id":"https://openalex.org/keywords/temozolomide","display_name":"temozolomide","score":1.0},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.5370000004768372},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.7490000128746033},{"id":"https://openalex.org/keywords/treatment-related-toxicity","display_name":"treatment toxicity","score":0.6140000224113464},{"id":"https://openalex.org/keywords/outpatient-therapy","display_name":"outpatient therapy","score":0.6499999761581421},{"id":"https://openalex.org/keywords/advanced-pancreatic-neuroendocrine-tumors","display_name":"advanced pancreatic neuroendocrine tumors","score":0.4970000088214874}],"concepts":[{"id":"https://openalex.org/C2777909004","wikidata":"https://www.wikidata.org/wiki/Q420207","display_name":"Capecitabine","level":4,"score":0.8328596949577332},{"id":"https://openalex.org/C2777389519","wikidata":"https://www.wikidata.org/wiki/Q425088","display_name":"Temozolomide","level":3,"score":0.8224053978919983},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7793757915496826},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.6548349857330322},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6543405652046204},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.5661850571632385},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.5432064533233643},{"id":"https://openalex.org/C2780580376","wikidata":"https://www.wikidata.org/wiki/Q186889","display_name":"Nausea","level":2,"score":0.5126473307609558},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4894953966140747},{"id":"https://openalex.org/C2778336483","wikidata":"https://www.wikidata.org/wiki/Q5090632","display_name":"Chemotherapy regimen","level":3,"score":0.4686068296432495},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.4223666787147522},{"id":"https://openalex.org/C2779066768","wikidata":"https://www.wikidata.org/wiki/Q1981276","display_name":"Neuroendocrine tumors","level":2,"score":0.41952696442604065},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.41559192538261414},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.38906699419021606},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2533286511898041},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.0}],"mesh":[{"descriptor_ui":"D000069287","descriptor_name":"Capecitabine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000077204","descriptor_name":"Temozolomide","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003606","descriptor_name":"Dacarbazine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D003606","descriptor_name":"Dacarbazine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008137","descriptor_name":"Longitudinal Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008279","descriptor_name":"Magnetic Resonance Imaging","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010190","descriptor_name":"Pancreatic Neoplasms","qualifier_ui":"Q000000981","qualifier_name":"diagnostic imaging","is_major_topic":false},{"descriptor_ui":"D010190","descriptor_name":"Pancreatic Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D010190","descriptor_name":"Pancreatic Neoplasms","qualifier_ui":"Q000532","qualifier_name":"radiotherapy","is_major_topic":true},{"descriptor_ui":"D015282","descriptor_name":"Octreotide","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D015282","descriptor_name":"Octreotide","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D015898","descriptor_name":"Tomography Scanners, X-Ray Computed","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018358","descriptor_name":"Neuroendocrine Tumors","qualifier_ui":"Q000000981","qualifier_name":"diagnostic imaging","is_major_topic":false},{"descriptor_ui":"D018358","descriptor_name":"Neuroendocrine Tumors","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D018358","descriptor_name":"Neuroendocrine Tumors","qualifier_ui":"Q000532","qualifier_name":"radiotherapy","is_major_topic":true},{"descriptor_ui":"D053208","descriptor_name":"Kaplan-Meier Estimate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1159/000434723","doi":"https://doi.org/10.1159/000434723","is_oa":false,"landing_page_url":"https://doi.org/10.1159/000434723","pdf_url":null,"source":{"id":"https://openalex.org/S84102376","display_name":"Neuroendocrinology","issn_l":"0028-3835","issn":["0028-3835","1423-0194"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310317820","host_organization_name":"Karger Publishers","host_organization_lineage":["https://openalex.org/P4310317820"],"host_organization_lineage_names":["Karger Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neuroendocrinology","raw_type":"journal-article"},{"id":"pmh:oai:pure.atira.dk:publications/87c715ca-792c-49a5-8bf6-5b6e4d5e1be3","doi":null,"is_oa":false,"landing_page_url":"https://research-repository.uwa.edu.au/en/publications/87c715ca-792c-49a5-8bf6-5b6e4d5e1be3","pdf_url":null,"source":{"id":"https://openalex.org/S4306402492","display_name":"UWA Profiles and Research Repository (UWA)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I177877127","host_organization_name":"The University of Western Australia","host_organization_lineage":["https://openalex.org/I177877127"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Claringbold, P & Turner, J H 2016, 'Pancreatic neuroendocrine tumor control: Durable objective response to combination 177 Lu-octreotate-capecitabine-temozolomide radiopeptide chemotherapy', Neuroendocrinology, vol. 103, no. 5, pp. 432-439. https://doi.org/10.1159/000434723","raw_type":"info:eu-repo/semantics/article"},{"id":"pmid:26065489","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/26065489","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neuroendocrinology","raw_type":"Clinical Trial, Phase II"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":36,"referenced_works":["https://openalex.org/W343836456","https://openalex.org/W1988986189","https://openalex.org/W2006830353","https://openalex.org/W2012856564","https://openalex.org/W2019607817","https://openalex.org/W2020409101","https://openalex.org/W2021676540","https://openalex.org/W2045173749","https://openalex.org/W2045927962","https://openalex.org/W2050083847","https://openalex.org/W2051800004","https://openalex.org/W2055850373","https://openalex.org/W2065832118","https://openalex.org/W2076597476","https://openalex.org/W2090232354","https://openalex.org/W2099051046","https://openalex.org/W2100030097","https://openalex.org/W2100283328","https://openalex.org/W2102617530","https://openalex.org/W2115686439","https://openalex.org/W2118672029","https://openalex.org/W2125398839","https://openalex.org/W2135049144","https://openalex.org/W2137142564","https://openalex.org/W2158474413","https://openalex.org/W2159009361","https://openalex.org/W2162830031","https://openalex.org/W2165147224","https://openalex.org/W2168123315","https://openalex.org/W2248652402","https://openalex.org/W2472016631","https://openalex.org/W2587663685","https://openalex.org/W2797028157","https://openalex.org/W2907907616","https://openalex.org/W3012528773","https://openalex.org/W4285719527"],"related_works":["https://openalex.org/W2012856564","https://openalex.org/W1988986189","https://openalex.org/W2050083847","https://openalex.org/W4378878015","https://openalex.org/W4226027666","https://openalex.org/W3007008362","https://openalex.org/W1596193789","https://openalex.org/W2899756322","https://openalex.org/W2933425479","https://openalex.org/W1453000988"],"abstract_inverted_index":{"BACKGROUND/METHODS:":[0],"Thirty":[1],"patients":[2],"with":[3,38,48],"advanced":[4,216],"progressive":[5,98,217],"grade":[6,169,180,190],"1":[7,130],"or":[8,172],"2":[9,170],"pancreatic":[10],"neuroendocrine":[11],"tumors":[12],"(pNETs),":[13],"treated":[14],"on":[15,100],"a":[16,116,207,220],"prospective":[17],"phase":[18],"II":[19],"single-center":[20],"study,":[21],"were":[22,139,160,188],"followed":[23],"up":[24,26],"for":[25,141,213],"to":[27,126,179],"4":[28,31,132,191],"years":[29],"after":[30],"cycles":[32,133],"of":[33,43,51,59,92,119,134,168,215],"7.9":[34],"GBq":[35],"177Lu-octreotate":[36],"combined":[37,45],"chemotherapy.":[39],"Each":[40],"8-week":[41],"cycle":[42],"treatment":[44,151],"radiopeptide":[46,204],"therapy":[47],"14":[49],"days":[50,58],"capecitabine":[52],"at":[53,61,115],"1,500":[54],"mg/m2":[55],"and":[56,74,84,137,143,155,184,194],"5":[57],"temozolomide":[60],"200":[62],"mg/m2.":[63],"RESULTS:":[64],"The":[65,150,162],"overall":[66,109],"response":[67,86,142],"rate":[68],"was":[69,76,105,124,152,165,177,199],"80%":[70],"(95%":[71,81,89],"CI":[72,82,90],"66-93),":[73],"there":[75],"complete":[77],"remission":[78],"in":[79,87],"13%":[80],"4-30)":[83],"partial":[85],"70%":[88],"52-83)":[91],"the":[93],"cases.":[94],"No":[95,122,145],"patient":[96,123],"manifested":[97],"disease":[99],"treatment.":[101],"Median":[102,108],"progression-free":[103],"survival":[104,110],"48":[106],"months.":[107,121],"had":[111],"not":[112],"been":[113],"reached":[114],"median":[117],"follow-up":[118],"33":[120],"lost":[125],"follow-up,":[127],"all":[128,138],"but":[129],"received":[131],"outpatient":[135,211],"therapy,":[136],"evaluated":[140],"toxicity.":[144],"one":[146],"required":[147],"hospital":[148],"admission.":[149],"well":[153],"tolerated,":[154],"no":[156,189,195],"serious":[157],"dose-limiting":[158],"toxicities":[159],"seen.":[161],"commonest":[163],"toxicity":[164,176],"transient":[166],"nausea":[167],"(33%)":[171],"3":[173,181],"(7%).":[174],"Hematological":[175],"limited":[178],"thrombocytopenia":[182],"(10%)":[183],"anemia":[185],"(10%).":[186],"There":[187],"adverse":[192],"events,":[193],"renal":[196],"functional":[197],"impairment":[198],"evident.":[200],"CONCLUSION:":[201],"Combined":[202],"177Lu-octreotate-capecitabine-temozolomide":[203],"chemotherapy":[205],"is":[206],"well-tolerated,":[208],"highly":[209],"effective":[210],"regimen":[212],"control":[214],"pNETs,":[218],"achieving":[219],"durable":[221],"objective":[222],"response.":[223]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W587945571","counts_by_year":[{"year":2026,"cited_by_count":9},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":14},{"year":2023,"cited_by_count":8},{"year":2022,"cited_by_count":10},{"year":2021,"cited_by_count":17},{"year":2020,"cited_by_count":13},{"year":2019,"cited_by_count":14},{"year":2018,"cited_by_count":13},{"year":2017,"cited_by_count":10},{"year":2016,"cited_by_count":4},{"year":2015,"cited_by_count":2}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
